Galectin Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies that target galectin proteins, particularly galectin 3, for the treatment of fibrotic diseases, cancer and other selected indications.

The company creates proprietary patented complex carbohydrates from plant based starting materials that bind and inhibit galectin 3, aiming to address conditions such as metabolic dysfunction associated steatohepatitis cirrhosis and certain cancers.

Galectin Therapeutics Inc does not yet generate revenue from commercial product sales and finances its operations through research collaborations, licensing agreements and equity financing.

Galectin Therapeutics Inc occupies a niche position in the biotechnology sector as one of the few companies developing therapeutic agents that directly inhibit galectin 3, a protein implicated in fibrosis, cancer progression and immune modulation; its competitive advantage lies in the proprietary platform of plant derived complex carbohydrates with defined molecular weights, which are protected by a substantial portfolio of patents covering composition of matter and methods of use; while larger pharmaceutical firms pursue monoclonal antibodies and small molecule inhibitors for similar indications, Galectin Therapeutics differentiates itself through its unique carbohydrate based chemistry and its focus on galectin mediated pathways.

Galectin Therapeutics Inc collaborates with research institutions and pharmaceutical partners to advance its clinical programs; specific collaborators include the Providence Portland Cancer Center, SBH Sciences Inc, Johns Hopkins University and the University of Chicago Medical Center.